22620-34-4 Usage
Description
(5-Chloro-3-pyridinyl)methanol is an organic compound with the molecular formula C?H?ClNO and a molecular weight of approximately 141.58 g/mol. It is a colorless to pale yellow liquid at room temperature and is characterized by its distinct chemical structure, which features a chlorinated pyridine ring and a hydroxymethyl group. (5-Chloro-3-pyridinyl)methanol is known for its reactivity and is commonly used as a synthetic intermediate in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
(5-Chloro-3-pyridinyl)methanol is used as a synthetic intermediate for the preparation of piperidines or piperidones substituted with urea and heteroaryl as FPR2 modulators. These modulators play a crucial role in the development of drugs targeting the formyl peptide receptor 2 (FPR2), which is involved in various physiological processes, including inflammation, pain, and immune response regulation. By modulating FPR2, these compounds have the potential to treat a range of conditions, such as chronic pain, inflammatory diseases, and certain types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 22620-34-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,6,2 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 22620-34:
(7*2)+(6*2)+(5*6)+(4*2)+(3*0)+(2*3)+(1*4)=74
74 % 10 = 4
So 22620-34-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H6ClNO/c7-6-1-5(4-9)2-8-3-6/h1-3,9H,4H2
22620-34-4Relevant articles and documents
SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
-
Paragraph 0321, (2015/07/02)
Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
Benzamides
-
, (2014/05/07)
The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor
Potential hypolipidemic agents. II. Preparation of 5-halo-3-pyridylmethanols.
Hedbom,Helgstrand,Misiorny,Stjernstroem,Westin
, p. 259 - 260 (2007/10/04)
-